Mutational spectrum and precision oncology for biliary tract carcinoma

Conclusions: Extensive genomic diversity and heterogeneity were observed among BTC patients, with contributions according to potential etiology exposures, anatomical subtypes and clinicopathological characteristics. We also demonstrated that patients with refractory BTCs who have PATs can derive considerable benefit from receiving a matched therapy, initiating further prospective clinical trials guided by molecular profiling among this aggressive cancer.

Source: Theranostics - April 19, 2021 Category: Molecular Biology Authors: Jianzhen Lin, Yinghao Cao, Xu Yang, Guangyu Li, Yang Shi, Dongxu Wang, Junyu Long, Yang Song, Jinzhu Mao, Fucun Xie, Yi Bai, Lei Zhang, Xiaobo Yang, Xueshuai Wan, Anqiang Wang, Mei Guan, Lin Zhao, Ke Hu, Jie Pan, Li Huo, Xin Lu, Yilei Mao, Xinting Sang, H Tags: Research Paper Source Type: research